Background: Guidelines for the use of antiretroviral agents for HIV-1 infection recommend
combining at least three agents. The toxicity, cost, and complexity of such regimens warrant …

The MONARK study was a pilot randomized trial comparing the safety and efficacy of
lopinavir-ritonavir (LPV/r) monotherapy to those of LPV/r-zidovudine-lamivudine triple …

Background The toxicities, cost and complexity of triple combinations warrant the search for
other treatment options, such as boosted protease inhibitor (PI) monotherapy. MONotherapy …

Background Daily oral triple therapy is effective at halting HIV disease progression, but can
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …

Objective: Evaluate efficacy and tolerability of lopinavir/ritonavir (LPV/r) plus stavudine and
lamivudine long term in antiretroviral-naïve patients. Design: Open-label follow-up of …

The importance of combination antiretroviral therapy in HIV-infection has been well
established. However, many available agents suffer shortcomings that limit their clinical …

Objective: Combination antiretroviral therapy with lopinavir/ritonavir (LPV/r) has been highly
effective in clinical trials. Results of long-term therapy with LPV/r-based regimens have not …

Objective: To evaluate virologic response rates of lopinavir/ritonavir (LPV/r) monotherapy as
second-line antiretroviral treatment (ART) among adults in resource-limited settings (RLSs) …

Background: Long-term adverse events and expenses associated with HAART have led to
an interest in simplified therapy. Lopinavir/ritonavir monotherapy is attractive due to its …

Objective To assess the rate of protocol-defined treatment failure and safety of
lopinavir/ritonavir (LPV/r) and saquinavir/ritonavir (SAQ/r). Design Open-label, prospective …